How wearable technology is optimizing the clinical research industry

wearables IIThe second, in a blog series about how advances in technology are impacting clinical trials. Read part I, here

Increasingly popular wearable technology has the potential to profoundly affect the possibilities for clinical research. Initially, some wearable devices, such as wristbands and smart watches, targeted consumers wanting to track their health and fitness level. Wearables allowed collection of data on a 24/7 basis as people went through daily routine activities. More recently, wearable devices are being designed and developed for use in clinical trials, with a real possibility of transforming the clinical research industry. Wearable devices are currently gaining huge popularity, with many technology companies developing wearables for entry into the clinical research space. These devices offer a vital opportunity to collect real-time data, to better understand patients’ needs, and to improve patients’ experience throughout participation in the clinical trial.

The most common use of wearable devices in clinical trials is to collect continuous real-time data from the participants. These devices can measure heart rate, gait, velocity, step count, sleep pattern, blood pressure, temperature and other parameters. Some more sophisticated devices are capable of measuring lung function and generating electrocardiograms. Non-invasive glucose monitoring is currently a target technology, and several companies are developing prototypes.  Some wearable devices can be paired with mobile applications to measure indicators such as tremor, balance, posture, and memory characteristics. This function can be of great importance in clinical trials of certain patient groups, such as those with Parkinson’s disease. The contemporaneous nature of data recording and the opportunity for more frequent measurement could reveal patterns for physiological changes, which would help determine the effect of a participant’s activity level on drug/device success.

Wearable devices may also make possible the remote monitoring of participants for adverse events (AE), which would certainly improve compliance with AE reporting. Wearables can continuously monitor participants’ vital signs, social interactions, sleep patterns, motor activity, and other markers of health. These physiological and behavioral changes that may indicate adverse events could provide robust, timely, and unbiased data for monitoring a participant’s status in a clinical trial. Wearable technology may be deployed within a wireless body area network (WBAN). WBAN devices can be implanted inside the body or attached to the exterior of the body. These devices include a number of wirelessly connected physiological sensors to help gather required data for a trial to monitor participant’s safety.

The possibilities of collecting real-time, highly objective time-marked data are exciting.  The future of wearable devices will not be limited to wristbands and smart watches.  Smart fabrics, ingestible sensors, and even smart lenses will be available soon for use in clinical trials. The use of these wearables will help to reduce the overall costs of running a trial by reducing the number of patient visits to the clinic and may improve participant compliance and retention.

A word of caution: despite the expected benefits of using wearable technology in clinical trials, the regulatory status with the FDA is not yet entirely clear. In addition, there will be a need for the data collected through these devices to be adequately validated for use. Evolving acceptance by regulators will help drive implementation of wearable technology in clinical research.

We would love to hear from you! What are your thoughts on wearable technology in the clinical research industry?

Visit to sign up for our newsletter and to learn more about how we can partner with you.

Contact us:

How are technological innovations affecting the clinical research process & likelihood of trial success?

Technology Clinical 2The first in a series of blogs about how advances in technology are impacting clinical trials.

New technologies are revolutionizing all industries, including health care and drug/device research. Technological innovations provide the potential to improve clinical trial efficiency and data accuracy by reducing patient burden and improving trial management. From wearable devices and smartphone apps for data collection to applications for trial management, the options to use technology in a clinical trial seem limitless. Technology’s rapid growth is challenging our traditional methods of running clinical trials by continually raising participants’ expectations, while also providing great opportunities for optimizing clinical trial management, patient recruitment and data collection.

Specifically, one of the most difficult things to accomplish in clinical trials is efficient patient recruitment. Recruitment failure has several consequences, including lack of usable findings from a trial, trial discontinuation, and financial loss. Successful patient recruitment and retention are common challenges that clinical trials face, but new technologies and platforms such as mobile applications are emerging to overcome this hurdle. These new technologies help keep investigators aware of the open clinical trials and communicate information efficiently across multiple locations in a large geographic area. There are many healthcare applications for mobile devices that help provide information to patients about their health.  These platforms have a large database of patients that may help the investigators and sponsors detect types of patients eligible for participation in a specific trial without disclosing any personal information. The technology platform then delivers personalized communications to the eligible patients to inform them of the clinical trial. In addition to identifying more potential trial participants than ever before, this approach simplifies for trial site staff the recruitment of patients by reducing administrative burden.

Another example of a quantum leap in clinical trial management enabled by technology is the advent of electronic data capture (EDC) systems. The change from paper-based data collection to EDC systems has revolutionized the process—making it possible to collate and analyze data from any location as soon as it is collected. This has also helped optimize patient safety by reducing data collection errors prior to the data review process. EDC systems can include clinical trial management system (CTMS) functionality, which can assist the user in tracking all essential trial documents and providing a snapshot of progress of a clinical trial.

In yet another advance, sensors and mobile technologies may be linked to the EDC system, making it possible to electronically collect patient-generated and patient-reported data which can then be automatically uploaded directly to the EDC system database. One of the most exciting capabilities of mobile technology is its real-time data collection feature. These features make data collection from everyday activities more accurate by collecting only the required clinical trial data in real-time. These capabilities can also lead to a decrease in clinic visits or follow-up phone calls for patients, making it easier and more cost-effective for patients to participate in a clinical trial.

Blockchain technology may provide another future key opportunity for sponsors to use in clinical trials. Blockchain is an electronic ledger that can be openly shared among users that creates an unchangeable record, each one linked to another with a time stamp. The use of this technology could potentially make it easier to securely store and share data. However, in the immediate future, a more realistic goal might be to use this technology to address issues around data integrity, reproducibility and transparency. For example, blockchain technology could support a robust process for collection of consents based on protocol revisions, storing and tracking the consent in a secure, traceable manner, and enabling highly reliable sharing of this information in real-time.

Another example of the Blockchain technology is the use of Smart Contracts to help effect transparent control over clinical trial activities occurring in the correct sequence.

In conclusion, the adoption of technology in clinical trials is on the rise. As more experience in the use of these technologies is accumulated, it will become increasingly clear how their use can significantly improve clinical trial outcomes.  In addition, the technologies will become less burdensome and will likely be widely adopted as clear improvements.

Visit to learn more about how we can partner with you.

Continue to follow our blog to view the upcoming posts in the technology series.

6 things sponsors or CROs can do to help sites be more efficient in clinical studies.


Successful execution of a clinical trial depends upon excellent working relationships between clinical research sites and sponsors. However, the rapport between sponsors and sites can sometimes become strained due to challenges in communicating effectively. With both parties working on numerous studies simultaneously, it can be difficult to address each other’s concerns in a timely manner.

To address this issue, it is important that both sites and sponsors (or their expert CRO delegates) actively maintain an open line of communication, and collaborate to eliminate miscommunication and obtain the best outcome possible for all involved, especially the patients being served.

Here are some useful tips for sponsors to consider when planning and conducting a clinical trial:

1. Ask your sites to explain barriers to estimating accurate potential trial enrollment rates

When it comes to filling out site assessment questionnaires, sites can provide a lot of valuable information beyond just a projected number of patients they can enroll in a week or a month. They can help identify potential barriers to achieving the desired enrollment rate.  Knowing this information, sponsors may be able to work proactively with their sites to eliminate these potential barriers.  There are many important factors that may affect patient enrollment and sites can provide the practical input needed to optimize patient recruitment and enrollment.

2.  Share enrollment updates with the study sites throughout the study and a summary at trial closure

During the enrollment phase of a trial, it is useful to share periodic enrollment updates with the sites.  The regular communication keeps them engaged with the trial, and it gives them some perspective as to how they are performing compared with the other trial sites.  Many times this will spur a friendly competition to try to be the trial’s top enroller (particularly since the various investigators are often colleagues who know each other personally).

At trial closure, the information tracked by the sponsor throughout the study must be analyzed and shared with all of the sites to compare realities with predictions. Sites can learn from past performance data, and use the information when considering future trials. This can help sponsors design future trials and plan recruitment strategies.

3. Avoid collection of redundant information from prior projects

Sponsors can use data collected from sites for previous projects, and evaluate site capabilities from this history, to reduce or eliminate the need for the sites to complete questionnaires when being considered for a trial. This will enable sites to use the saved time for more robust study start-up efforts and plan to increase study success.

4. Consider inputs from sites for better trial design

One of the best paths to study success is to involve trial sites before the protocol is finalized. If sites have a chance to evaluate the draft inclusion/exclusion criteria and data collection methods and time points, they can determine how difficult it would be for the site staff to implement the trial as designed. These inputs can provide improvements in accuracy of anticipated patient costs and trial timelines. Additionally, these inputs can prevent last minute surprises and challenges during trial progress.

5. Let sites know why they were not selected for the trial

It is important to provide sites with feedback when they are not chosen to participate in a trial. Sites typically don’t receive detailed information from the trial sponsor, just a rejection notification. Sponsors should provide sites with reasons for not being selected to help them improve and to build a good relationship for the long-term. Obviously this will not benefit the current trial, but it may give the site justification to address some of the shortcomings in its preparedness to conduct clinical trials or give the site insight needed to better target trials suited to its strengths.  This will lead to increased success in future trials, perhaps even one of yours.

6. Provide access to database systems for operational needs

Most sites don’t have enough funds to purchase database management systems like Clinical Trial Management Systems (CTMS). Sponsors realize the importance of data management systems and can consider providing sites access to CTMS systems to track their progress and simplify their operational and reporting needs. This can save staff time, and enhance accuracy and consistency of data.

Early planning and consistent communication with clinical sites can help move your trial along more efficiently. If you have any questions, or if you would like to discuss this topic in more detail, please email

Please visit to learn more about how we can partner with you and help drive success in your clinical studies.

IHIF Annual Gala Dinner

On September 13th, MED had the opportunity to be a sponsor at the 2017 IHIF Annual Gala Dinner. The IHIF is an outstanding organization that works to connect key stakeholders to enhance business networks advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation. The Annual Gala Dinner was held at the beautiful Alexander, A Dolce Property in Indianapolis, IN. The evening started with a general reception in the Gallery and special VIP Event with the keynote speaker. The meeting included an IHIF organizational and industry update, presentation of the Legislator of the Year award, and focused on Alzheimer’s disease. The feature on Alzheimer’s was made possible through a partnership between IHIF and the Alzheimer’s Association, Greater Indiana Chapter.

Dr. Bruce Lamb, Director, Stark Neuroscience Research Institute with Indiana University School of Medicine presented “Alzheimer’s Research in Indiana”. Dr. Lamb’s presentation covered the disease state, current treatment modalities, difficulties studying the disease, recent advancements, and increased funding that is becoming available. Dr. Lamb’s research has focused on the basic disease mechanisms of Alzheimer’s disease and has shed light on how complex mechanisms associated with Alzheimer’s have hindered efforts to find effective treatments in clinical trials.

IHIF-Image.jpg2Pictured from left to right: Dan Peterson, Vice President Industry & Government Affairs at Cook Medical, Justin Renfrow, Contracts Director at MED Institute, Matthew Waninger, President at MED Institute, and Brooke Corcoran, Marketing Specialist at MED Institute.

To learn more about how we can partner with you, please visit

5 Tips for Medical Device Sponsors for Running a Successful Clinical Trial

5 tips2

Everyone is demanding more clinical evidence from medical device companies these days. FDA wants to see more clinical data before and after granting approval for marketing devices. Hospitals and physicians are asking for more of it when making purchasing decisions. This pressure is forcing medical device companies to collect more clinical data on their devices than ever before, and they primarily are responding by running more clinical trials to distinguish their products from competitors. However, most medical device companies lack internal resources and capability to run a complete clinical trial operation in-house. This is mostly true for small and start-up companies, which have little to no experience in running a clinical trial. As a result, we are observing a consistent rise in the outsourcing of clinical services to contract research organizations (CROs). Selecting the right CRO to manage a clinical trial can be a critical decision in a company’s successful outcome. Here are the five tips for medical device companies or sponsors to consider when subcontracting clinical trials to a CRO:

  1. Selecting a CRO with medical device expertise

Most CROs are focused on running pharmaceutical trials and lack sufficient medical device trial experience. When CROs give you a presentation and start talking about 1572s and Phase II/III studies, you know they have not conducted trials on medical devices. The basics of running pharma and medical device trials are the same, but there are some significant differences that cannot be overlooked. The ideal CRO for your trial will have demonstrated success running clinical studies in your product’s therapeutic area.

  1. Creating an internal clinical research team

Outsourcing doesn’t mean completely turning over the reins to your CRO. Nobody knows your product better than you do, and the CRO is going to need your guidance, feedback and support based on your expertise. Hence, it is important for a sponsor to form at least a one-member team who will be committed to this job. This person or team will be fully involved in the process, and ultimately be responsible for project outcomes.

  1. Engaging vendors early in the process

Sponsors need to initiate communication with prospective vendors as early as possible in the start-up process. This benefits sponsors by connecting with all clinical teams and laying the groundwork for future interactions. Having several meetings with the sponsor and outsourced staff prior to start-up can keep all parties apprised of trial protocols and progress.

  1. Having effective risk management processes

In reality, all projects have a mix of risks, problems and uncertainties. Hence, sponsors must not expect all the plans and schedules that are developed will happen exactly as planned. Sponsors must set more realistic timeline targets. Feasibility assessments are done in an effort to de-risk the study, although it may or may not reduce the uncertainty. Sponsors must create action plans and allocate funds to enable them. Risk management greatly improves the predictability of project outcome in terms of time and cost.

  1. Having full transparency for collaborative partnership

Sponsors should be open with a CRO about what exactly they need from the agreement, what they can afford, and the project scope. This will help them work with CROs in true partnership. Sponsors and CROs need single-view analytics and ability to collaborate through data-driven tasks and workflows. The advantages of building a collaborative relationship with your CRO can be significant.

To learn more about our clinical services and how we can partner with you, please visit

Is the Pre-Submission process worth the time and effort?

The last in a series of blogs about informal, pre-submission contact with FDA.  Visit our website for the previous six.

Med_D6A1047The Pre-Sub process can be time-consuming (Pre-Sub; see FDA guidance here). You may wonder if it’s worth it. We discussed some of the reasons for having a Pre-Sub (or not having one) in a previous post, but let’s look at those again:

  • Is the device new (to you) or FDA?
  • How well do guidance documents, recognized consensus standards, or 510(k)/PMA summaries apply?
  • Where are you in the development cycle?
  • How expensive is it to be wrong?

Those are the “hard” questions to ask before you decide, but there are a few more “soft” reasons for asking for a Pre-Sub:

  • It is a valuable opportunity to make a good first impression.
  • It is a great way to sort out major issues in a non-adversarial manner.
  • It is a great way to educate FDA on your new device, technology, or test.

This last one is especially important. You may have 100% confidence in your development program. But if FDA has never seen this type of device before, it is helpful if they are exposed to it proactively. The back-and-forth of the Pre-Sub program gives you time to explain your device before your formal submission, when table upon table of data arrive at their doorstep unannounced.

MED believes it is important to integrate your engineering and regulatory strategies from the very beginning of the medical device development process, if possible, or at least as early in the process as you can. The Pre-Submission (Pre-Sub) process is a perfect opportunity to present both your engineering strategy and your regulatory strategy to FDA early in the process and ensure that everyone is in agreement.

We all have the same goal: to help patients by providing innovative and safe medical devices. Keeping this common goal in mind during our interactions will help us to focus on the supporting data and risk mitigation tools that support that goal. We can also develop trust and foster meaningful relationships with the agency in the process.

To have a more thorough discussion or to answer any questions you may have regarding the Pre-Sub process or tips on how to effectively communicate with FDA, please contact MED Institute via our website at

What happens once I submit a Pre-Submission? (Part 3: After the meeting)

The sixth in a series of blogs about informal, pre-submission contact with FDA. See here, here, here, here, and here for the previous five.

MED Inst, Med,  regulatory science, regulatory dataYou have sent FDA a Pre-Submission (Pre-Sub; see FDA guidance here) to get answers to questions you want to know well before your formal submission (e.g., an IDE or 510(k)). You have received comments from FDA, and met with them to discuss them. What’s next?

Minutes: Within 15 calendar days of the teleconference or in-person meeting, you will draft meeting minutes and submit them to FDA. FDA will review and edit the meeting minutes, if necessary, within 30 days of receipt. The final version will become the final record of the meeting or teleconference 15 calendar days after you receive FDA’s edits. If you disagree with FDA’s edits, you can submit an amendment and FDA will discuss them with you.

Don’t try to capture everything that was said, just important agreements (or disagreements) and action items. The process may seem tedious, but it is often a good opportunity to get further clarification on FDA’s thinking and to clear up any misunderstanding.

Issues needing further discussion: As mentioned in a previous post, you only have 60 minutes, so you may not have time to discuss some of the lesser points of disagreement. Many of these can be handled with supplements to the original Pre-Sub. Talk to your lead reviewer about how to structure the discussion.

FDA’s commitment: In the Pre-Sub guidance, FDA has committed to standing by their feedback, with the following conditions: information in the formal submission is consistent with the Pre-Sub interaction, the data in the subsequent submission do not raise new important issues, and no material issues have arisen since the time of their feedback, e.g., new scientific findings about risks.

It is not unreasonable to be wary of this commitment, especially the caveat about “new scientific findings”. If there is a long gap between the meeting and the final submission, consider whether you will need to double-back with FDA.

Future submissions: All of your work will go to waste if you don’t remind FDA what was agreed upon when your formal submission (e.g., IDE, 510(k), PMA) is submitted. Those formal submissions should include a copy your questions, FDA’s comments, the meeting minutes, detailed responses to each of FDA’s comments, and cross-reference to the same information in the main body of the submission.

For instance, suppose your Pre-Sub asked a question about the types of bench tests to be conducted. FDA responded that they agreed to the test matrix, but they wanted you to do two more tests. The meeting minutes reflect that you agreed to the first additional test, but not the second one. In this case, the appendix to the formal submission should include your original question, a clear statement that FDA agreed to it with reservations, and (1) a reference to the location of the agreed-upon tests in the main body, and (2) a well-supported justification about why the remaining test was unnecessary.

For more information, please visit our website at

Next time: Is the Pre-Sub Process worth the time and effort?

What happens once I submit a Pre-Submission? (Part 2: The meeting)

The fifth in a series of blogs about informal, pre-submission contact with FDA.  See here, here, here, and here for the previous four.

MED Inst, Med,

You have sent FDA a Pre-Submission (Pre-Sub; see FDA guidance here) to get answers to questions you want to know well before your formal submission (e.g., an IDE or 510(k)). For instance, your clinical study involves novel technology and/or methods to assess effectiveness and you want FDA’s buy-in before you go too far down the road. You are convinced of the methods, but you know they are new to FDA, so you want to explain them in a face-to-face setting and make sure they understand them. A few other questions have come up too, so you will cover them.

The meeting will only last 60 minutes, so you will need to focus your efforts on key points of confusion or disagreement. Here are some key points to consider:

  • The guidance recommends that your formal presentation be limited to one-third of the allotted meeting time. We think even less is better. Can you say what you need to say in 10 minutes? The meeting is intended for discussion. If you spend too much time in your initial presentation, you will hear less of what they are thinking. We often use the format of “Here is our question; here is your response; here are our thoughts on your response; let’s discuss;” for each question that was raised.
  • Do not spend time repeating previous information. Do not talk about your company; talk about the device only to briefly remind people of it and bring up any features that may be the subject of their questions and comments.
  • Rehearse the presentation and the meeting dynamics before the meeting. Who is in charge of introductions? Who gives the formal presentation? Who manages the meeting flow and fields questions? To whom does the meeting manager turn when they can’t answer a question? To whom does the fielder redirect for various types of questions? What sort of questions will FDA raise?  Who answers them and how? Who takes minutes? If you are bringing outside experts, make sure they understand what you expect of them.
  • However, do not over-rehearse. Your manner should be relaxed, not antagonistic or stiff, but still keep your eye on the goal of getting to a mutually satisfying resolution. With only 60 minutes, you do not have time for getting sidetracked.
  • Always start with thanking FDA for their comments. If you have points of agreement with FDA’s comments (e.g., you are willing to increase the sample size or use the animal model they suggested), then let them know that right away.
  • “Why” is always a good question for these types of meetings. You want to understand why FDA said what they said. So just politely ask them. Once they have explained, you may find yourself in agreement with them! Or you can propose a different solution and/or explain in more depth why you took your original position.
  • Do not bring new data into the discussion or, if you do so, be careful about how and when you do it. The guidance states that, in most cases, FDA will only be able to respond to the questions or issues that were included in your meeting request or background information, not on new information presented during the meeting. If you do bring up new information, it’s best to couch it with the caveat, “We know this is new information, but we think it is relevant…” and then try not to force an immediate response.

Should you have this meeting over the phone or in person? As you can see from the list above, much of this is far more effective when everyone can see each other. Conversations are more spontaneous and relaxed. People are less likely to speak over one another or wait overly long as can often happen on a conference call.

Here is a second reason to have your meeting in person.  The written comments are the collective opinion of FDA. But when you meet with them in person, you may be exposed to a diversity of opinions and viewpoints within the Agency. Several times, we have come to realize that a particular FDA team member was driving what seemed to be an unreasonable request. When the entire team is assembled and we’ve had an opportunity to explain things further, FDA’s opinion changed.

We are happy to help at any stage along the way, including preparing for the meeting, but it is best for all to be involved from the very beginning. For more information, please visit our website at

Next time:  After the Pre-Submission meeting.

What happens once I submit a Pre-Submission? (Part 1: Before the meeting)

The fourth in a series of blogs about informal, pre-submission contact with FDA.  See here, here, and here for the first three.


You have sent FDA a Pre-Submission (Pre-Sub; see FDA guidance here) to get answers to specific questions well before your formal submission (e.g., an IDE or 510(k)). For instance, your technology is very new to the medical device world and you want to make sure that FDA agrees with your testing plan. What happens next?

  1. Initial acceptance review; setting the date. FDA will perform an “acceptance review” within 15 calendar days of receipt to make sure all the required elements of a Pre-Sub have been included in your submission. After that, they will contact you about setting a date and time for the in-person meeting or phone call.
  2. FDA internal review. The meeting typically occurs about 90 days after receipt of the Pre-Sub, with a commitment to provide you written feedback a few days before the meeting. FDA will create a team to review the matter, discuss your questions, and finalize their comments. You may get a phone call or email along the way, asking for clarification. As the meeting date approaches, it is advisable to reconfirm the date and time as well as FDA’s proposed list of attendees. Make sure that your expertise matches theirs. If they are including an engineer or statistician, make sure you have one too.
  3. FDA’s written feedback. FDA will answer your questions and provide you with additional comments. Those additional comments are as valuable as the answers to your questions. If the feedback is all positive, you may decide to cancel the meeting, but in our experience there are always more questions to be discussed.
  4. Before your meeting with FDA. The guidance states that FDA wants your presentation slides at least two business days before the meeting, but since you will have just received FDA’s comments, you will probably spend most of your time sorting out how you want to respond,so don’t feel an obligation to send the slides.

In our experience, the time between receiving FDA’s comments and preparing for the meeting is usually very intense. You have received feedback on your questions. You have likely received extra feedback. Some of it is clear, some of it is not, some of it is adverse, and some of it is supportive. Your meeting will last only 60 minutes. What topics do you cover?

It helps to remember that the Pre-Sub program is a process. You may need to come back later, perhaps via email, to discuss some of the minor points. MED Institute has considerable experience with Pre-Sub meetings. We are happy to help at any stage along the way.

For more information, please visit our website at

Next time:  The Pre-Submission meeting.

What is involved when submitting a Pre-Submission?

The third in a series of blogs about informal, pre-submission contact with FDA. See here and here for the first two.

You have decided to ask FDA a question or questions that you want answered well before your formal submission (e.g., an IDE or 510(k)), so that you can save valuable time and money in the long run. For instance, you want to know if you’re doing the right large animal study or have the correct sample size for your expensive bench test.

RegulatoryThe Pre-Submission (Pre-Sub) program (see FDA guidance here) describes the contents of the submission you need to write  to get your questions answered. It is a long guidance, but not too hard to understand, especially if you have a specific product in mind. We’ll use this blog to cover some strategy and tactics we’ve learned over the years about what should go in the submission itself.

  • Cover Letter: This is fairly boilerplate. Introduce yourself, ask for the meeting, propose at least 3 dates to meet or talk, state who is attending, and who from FDA you want to attend. FDA typically limits the meetings to 60 minutes, so if you have a great deal to discuss, you can always plan on more than one Pre-Sub interaction; for example, the first to discuss non-clinical testing and the second to discuss a clinical protocol.
  • Device Description and Indications for Use: The “Goldilocks” principle applies here. Not too much, not too little. Write enough so that FDA can understand the questions you are asking, but don’t provide unnecessary detail.
  • Previous discussions or submissions; Overview of product development: Keep it brief. FDA doesn’t need to know the details.
  • The background for the question you are asking: This is the key section of the submission and, again, the Goldilocks principle applies. You want to give them enough background to understand the questions you are asking and the information that supports your proposed or desired answer. Answer possible objections, but don’t add details that aren’t relevant or else FDA may misunderstand your position.
  • Specific questions: Figuring out which questions to ask and how to ask them can be a challenge. Don’t ask, “What should I do?” Instead ask, “Do you agree with this approach?”
  • Method for feedback (writing only, meeting, phone): We strongly encourage you to meet with FDA in person at least once. It helps them feel comfortable with you. It helps you understand them better.

There is so much more to writing a Pre-Sub than these brief highlights. Each Pre- Sub has its unique challenges and all of them must be written carefully. We would be happy to be a sounding board, coach you through the process, write the submission for you, and/or coordinate the meeting.

For more information, please contact MED Institute via our website at

Next time:  What happens once I submit a Pre-Submission?